Therefore, reducing MMP-9 and IL-8 production by suppression of Shp2 signaling may be preventing both pulmonary remodeling and inflammation in the diseases associated with CS, making Shp2 inhibition a putative therapy for COPD and lung cancer [48]. This evidence concerns the gene MMP9 and lung carcinoma.